Desoximetasone

For the long-term management of chronic inflammatory skin diseases such as atopic dermatitis and psoriasis, the clinical demand for balancing the potency and safety of topical glucocorticoids continues to rise. As a representative variety of medium-potency fluorinated glucocorticoids, desoximetasone binds to intracellular glucocorticoid receptors, inhibits the production of inflammatory mediators, and reduces the infiltration of immune cells, which can quickly relieve symptoms such as skin erythema, pruritus, and thickening. It is suitable for the treatment of a variety of corticosteroid-responsive skin diseases in adults and children over 2 years old. Compared with non-fluorinated glucocorticoids of the same category, it has a lower risk of systemic adverse reactions after transdermal absorption, and is suitable for short-term standardized use on thin and tender skin areas.

The global market size of topical glucocorticoids was approximately USD 8.7 billion in 2023, among which medium-potency glucocorticoids accounted for nearly 42%. As a second-line drug recommended by clinical guidelines, desoximetasone has maintained a compound annual growth rate of 3.8% in the past three years, and its growth momentum mainly comes from the improvement of the diagnosis and treatment rate of skin diseases in developing countries. The domestic market is still dominated by imported preparations at present, and the generic drug declaration is still in the early stage, with no publicly verifiable market size statistics. With the expansion of the topical dermatological drug market, there is a certain market space for its generic drug substitution.

The original research enterprise of desoximetasone is Bayer HealthCare, and the original brand name is Topicort. The compound patent in the US market expired in 1986, and no relevant compound patent registration information has been found in China for the time being. The main dosage forms approved for the original product include cream and ointment, with two specifications of 0.05% and 0.25%. Among them, the 0.05% cream has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in the Chinese *List of Chemical Drugs*. As of the time of retrieval, there is no valid registration information of desoximetasone on the API registration platform of China National Medical Products Administration Center for Drug Evaluation (CDE), and there is no desoximetasone preparation approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for desoximetasone API, covering impurities at each stage of the synthesis route and degradation impurities. Most products are available from stock, and in-stock products ordered before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can meet the full-process requirements of API R&D, quality research, registration and declaration, etc.